metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)
versus placebo
	nivolumab alone
	CheckMate 577, 2021 N Engl J Med 2021 Apr 1;384(13):1191-1203. NCT02743494	RCT	mEC - (neo)adjuvant (NA)	nivolumab	placebo	as adjuvant therapy in patientswith locally advanced (Adults with resected (R0)stage II or III) esophageal or gastroesophageal junction cancer with predominant adenocarcinomaor squamous-cell carcinoma.	532 / 262	some concern	conclusif	demonstrated 37 % decrease in events or deaths (EFS) (PE)
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	nivolumab alone
	ATTRACTION-3, 2019 Lancet Oncol 2019 Nov;20(11):1506-1517. NCT02569242	RCT	mEC - 2nd line (L2)	Nivolumab	ICC Docetaxel/Paclitaxel	Patients With Unresectable Advanced or Recurrent (squamous or adenosquamous) Esophageal (including the oesophagogastric junction) Cancer who have failed in standard chemotherapies.	210 / 209	high	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) statistically significant 64 % decrease in DCR